PBYI

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2010, for Innovative Acquisitions Corp. (Note: The input metadata references "PUMA BIOTECHNOLOGY, INC.", but the filing text explicitly identifies the registrant as Innovative Acquisitions Corp.). The company is a Delaware corporation classified as a "shell company" and a "blank check" company. It was formed to pursue a business combination through the acquisition of or merger with an operating business. As of the reporting date, the company has no specific business plan other than seeking a target and has generated no revenue since its inception on April 27, 2007.

Key Financial Metrics

Note: The filing does not provide margin data as there is no revenue. The company is funded entirely by capital contributions from directors and stockholders.

Material Changes vs. Prior Period

• Liquidity: Cash decreased from $2,408 at December 31, 2009, to $2,100 at September 30, 2010, a reduction of $308.
• Liabilities: Accounts payable decreased from $2,270 at December 31, 2009, to $0 at September 30, 2010, indicating the settlement of prior obligations.
• Operating Loss: The net loss for the nine months ended September 30, 2010, was $10,338, compared to $13,524 for the same period in 2009, representing a slight decrease in burn rate.
• Capital Contributions: The company received $12,300 in additional cash capital contributions from directors during the nine months ended September 30, 2010, with no new shares issued.

Outlook, Risks, and Management Commentary

• Going Concern: Management explicitly states that the company has not generated revenue and is unlikely to do so in the immediate future. The continuation of the company as a going concern is dependent on financial support from shareholders and the ability to obtain equity financing. This raises substantial doubt regarding the company's ability to continue operations.
• Business Plan: The company intends to identify a target for a reverse merger or acquisition. It has no specific timeline or plan to identify a target. Management anticipates incurring costs for SEC filings and acquisition investigations over the next 12 months.
• Funding Strategy: The company relies on funds in its treasury ($2,100), deferral of fees, and additional advances from stockholders or management. There are no formal agreements guaranteeing these future advances.
• Risks: Risks include the inability to secure additional funding, the failure to find a suitable acquisition target, and the inherent risks of merging with a financially unstable or early-stage company. The company is also subject to regulations limiting the sale of "blank check" securities in many jurisdictions.
• Related Party Transactions: The company's principal office is located at a related party's address on a rent-free, month-to-month basis.

Investor Verification Checklist

• Verify the discrepancy between the metadata company name ("PUMA BIOTECHNOLOGY, INC.") and the actual registrant ("Innovative Acquisitions Corp.") to ensure the correct entity is being analyzed.
• Confirm the status of the $2,100 cash balance and whether it is sufficient to meet upcoming SEC filing fees and operational costs for the next 12 months.
• Assess the likelihood of receiving further capital contributions from directors, given the lack of formal funding agreements.
• Review the company's progress in identifying a specific acquisition target, as no target has been identified since inception in 2007.
• Check for any updates on the "Going Concern" status in subsequent filings, as the company has no revenue stream.